期刊文献+

肺母细胞瘤临床病理特征分析 被引量:1

Clinicopathological characteristics and differential diagnosis on pulmonary blastoma
下载PDF
导出
摘要 目的探讨肺母细胞瘤的临床病理特征。方法回顾性分析1987年1月至2013年9月8例肺母细胞瘤的临床病理资料,8例肺母细胞瘤中成人占6例,其中经典的双相型肺母细胞瘤4例,由原始上皮成分和原始间叶成分共同组成;上皮型肺母细胞瘤2例,由分化较好的形态类似于子宫内膜样的腺体构成。其它2例为小儿胸膜肺母细胞瘤,由恶性胚胎性间叶成分构成。对肿瘤组织进行免疫组化染色及EGFR基因突变检测。结果免疫组化染色显示原始上皮成分广谱CK、EMA、TTF1、β-catenin阳性,原始间叶成分Vimentin阳性,桑葚体结构CgA和Syn阳性。所有病例EGFR基因突变检测显示EGFR基因18~21号外显子无突变,均为野生型。结论肺母细胞瘤是罕见的肺原发性恶性肿瘤,免疫组化染色有助于明确诊断。 Objective To investigate clinicopathological characteristics and differential diagnosis of pulmonary blastoma ( PB) .Methods The clinical pathological data of 8 patients from Jan.1987 to Sep.2013 were reviewed retrospectively. Six cases were adults with the age range of 27-53 ( mean 42 ) .Four of them were classic biphasic pulmonary blastoma ( CBPB) which were composed both of the primitive epithelial and stromal components.Two of them were epithelial type pulmonary blastoma which was composed of well differentiated tubules resembling endometrioid gland.The other two cases were children with pleuropulmonary blastoma which was composed of malignant embryonic stroma and non-neoplastic epi-thelium.CK, EMA, Nse, CgA, Syn, Vimentin, SMA, Des, S100, CD34, TTF1,β-catenin were detected by immuno-histochemistry and EGFR mutation in exon 18-21 was detected by ARMS.Results The pan-CK, EMA, TTF1 andβ-catenin were positive in the epithelial component, vimentin positive in the stromal component, and CgA and Syn was posi-tive in the structure of morula.EGFR mutation in exon 18-21 were not detected in all the 8 cases.Conclusion Pulmonary blastoma is a rare primary lung malignancy.The immunohistochemical staining is helpful for its diagnosis.
出处 《大连医科大学学报》 CAS 2015年第5期455-460,共6页 Journal of Dalian Medical University
基金 国家自然科学基金项目(81200545) 陕西省国际科技合作重点项目(2014KW21-01)
关键词 肺母细胞瘤 临床病理学 诊断 pulmonary blastoma clinicopathology diagnosis
  • 相关文献

参考文献5

二级参考文献40

  • 1Linardou H,Dahabreh IJ,Bafaloukos D,et al.Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.Nat Rev Clin Oncol,2009,6(6):352-366.
  • 2Herbst RS,Heymach JV,Lippman SM.Lung cancer.N Engl J Med,2008,359(13):1367-1380.
  • 3Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib.N Engl J Med,2004,350(21):2129-2139.
  • 4Paez JG,Janne PA,Lee JC,et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy.Science,2004,304(5676):1497-1500.
  • 5Rosell R,Moran T,Queratt C,et al. Screening for epidermal growth factor receptor mutations in lung cancer.N Engl J Med,2009,361 (10):958-967.
  • 6Pao W,Miller V,Zakowski W,et al.EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefltinib and erlotinib.Proc Natl Acad Sci U S A,2004,101(36):13306-13311.
  • 7Horn L,Sandler A.Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer.Clin Cancer Res,2009,15(16):5040-5048.
  • 8Pao W,Ladanyi M.Epidermal growth factor receptor mutation testing in lung cancer:searching for the ideal method.Clin Cancer Res,2007,13 (17):4954-4955.
  • 9Endo K,Konishi A,Sasaki H,et al.Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.Lung Cancer,2005,50(3):375-384.
  • 10Tsao MS,Sakurada A,Cutz JC,et al.Erlotinib in lung cancermolecular and clinical predictors of outcome. N Engl J Med,2005,353 (2):133-144.

共引文献766

同被引文献1

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部